Hadassah Medical Center -

Home

About

Med Services

Medical Departments

Clinics and Institutes

Central Laboratory

Health Services

Centers of Excellence

News

Press Releases

Press Clips

Medical Forefront

Publications

International Patient

Contact

Home > Physicians, Dentists, Investigators

Physicians, Dentists, Investigators

Prof. David Varon

Head, Thrombosis and Hemostasis Unit

Department of Hematology

Hadassah University Hospital

Ein-Karem, Jerusalem

Prof. David Varon was born in Israel and trained at the Tel Aviv University, where he received his MD diploma in 1976.

He did his medical residency at Kaplan Hospital, and concurrently, performed his basic science project at the Weizman Institute.

He was a Fellow in Hematology in a research capacity at New York University from 1981-1983, where he worked with the highly respected and renowned expert in blood clotting, Dr. Simon Karpatkin on the antigenic epitopes of ITP platelets. They were the first to establish the GPIIb-IIIa as an antigen in this disease.

He returned to Israel 1984-1987, where he completed his clinical training in Hematology in Kaplan Hospital.

Following this, he again returned to the United States, to work for 2 years at the Scripps Institute in La Jolla, California (1990-1991).

From 1987 to 2000, he was the Deputy Director of the National Hemophelia Center at Sheba Medical Center, and from 1998-2001, he was the director of the Blood Banking and Transfusion Service at Sheba Medical Center. As such, Prof. Varon has a vast amount of clinical experience with treating blood clotting disorders from which to draw upon.

He holds the academic rank of Senior Lecturer from the Tel Aviv University and Associate Professor from the Hebrew University, Jerusalem.

In 2001, Prof. Varon was recruited to head the Thrombosis and Hemostasis Unit of Hadassah Medical Organization, and he has already attained the status of a highly valued member of our Staff. He has a major input into the management of patients with disorders of bleeding, and in addition, of patients with hypercoagulable states.

His expertise is called upon in his role of consultant to many of the hospital’s inpatient departments. In particular, he has a close working relationship with the Obstetrics and Gynecology Department, which frequently seeks his advice in the management of coagulation problems in pregnant and postpartum patients.

He has a very active outpatient clinic, treating patients who require short or long term anticoagulation. He is also an expert on the treatment of hereditary and acquired bleeding disorders.

He has extensive teaching responsibilities lecturing to 4^th and 6^th year students.

List of Publications

1. Varon D. & Karpatkin S.: A monoclonal anti platelet antibody with decreased reactivity for autoimmune thrombocytopenic platelets. Proc. Natl. Acad. Sci. 80: pp.6992-6995, 1983.

2. Zucker M.B., Varon D., Karpatkin S. & Masiello N.: The combining ability of glycoproteins IIb & IIIa in EDTA - treated non aggregable platelets. Thromb. Haemost. 4: pp.848-851, 1983.

3. Lugassy G., Hurwitz N., Shtalrid M., Varon D., Marshak G. & Berrebi A.: Clinical and pathological features of non-Hodgkin's lymphoma of the tonsil. Review of the literature and report of ten cases. Isr. J. Med. Sci. 25: pp.251-255, 1989.

4.Lugassy G., Vorst E.J., Varon D., Sigler E., Shani A., Bassous-Guedj L., Hurwitz N. & Berrebi A.: Carcinocytemia: report of two cases, one simulating Burkitt lymphoma. Acta Cytol. 54: pp.265-268, 1990.

5. Varon D., Linder S., Gembom E., Guedj L., Langenboim H., Berrebi A. & Eshhar Z..: Human monoclonal antibody derived from an autoimmune thrombocytopenic purpura patient, recognizing an intermediate filament's determinant common to vimentin and desmin. Clin. Immunol. Immunopathol. 70: pp.274-277, 1990.

6. Martinowitz U., Mazar A., Rakocz M., Varon D., Ramot B., Heim M. & Taicher S.: Dental extraction for patients on oral anticoagulant therapy. Oral Surg. Oral Med. Oral Pathol. 70: pp.274-277, 1990.

7. Heim M., Horoszowski H., Lieberman L., Varon D. & Martinowitz U.: Methods and results of radionucleotide synovectomies. Ort. Traum. Oggi 10(1): pp.30-32, 1990.

8. Heim M., Horoszowski H., Varon D. & Martinowitz U.: The indications for orthotic devices in haemophilia therapy. Ort. Traum. Oggi 10(1): pp.67-69, 1990.

9. Lusher J.M., Salzman P.M. and the “Monoclate¨ study group: Viral safety and inhibitor development associated with factor VIIIC ultra-purified from plasma in hemophiliacs previously unexposed to factor VIIIC concentrates. Sem. Hematol. 27 (suppl.2): pp.1-7, 1990.

10. Brenner B., Schwartz S., Ben-Porath E., Tatarsky I., Varon D. & Martinowitz U. The prevalence and interaction of human immunodeficiency virus and hepatitis B virus infections in Israeli hemophiliacs. Israel J. Med. Sci. 27(10): pp.556-561, 1991.

11. Levene N.A., Varon D., Shtalrid M. & Berrebi A.: Chronic active hepatitis following splenectomy for autoimmune thrombocytopenia. Isr. J. Med. Sci. 27(4): pp.199-201, 1991.

12. Martinowitz U., Varon D., Yonash P., Bar-Maor A., Brenner B., Leibovitch I. & Heim M..: Circumcision in hemophilia: the use of fibrin glue for local hemostasis. J. Urol. 148: pp.855-957, 1992.

13. Martinowitz U., Schulman S., Gitel S., Horozowski H., Heim M & Varon D.: Adjusted dose continuous infusion of factor VIII in patients with haemophilia A. Brit. J. Haematol. 82:729-734, 1992.

14. Lavee J., Raviv Z., Smolinsky A., Savion N., Varon D., Goor D.A. & Mohr R.: Platelet preservation and improved hemostasis during cardiopulmonary bypass; a scanning electron microscope study. J. Thorac. Cardiovasc. Surg. 55:114-119, 1993.

15. Varon D., Handsher R., Dardik R., Gitel S.N., Ra'anani P., Heim M. & Martinowitz U. The response of hemophilic patients to poliovirus vaccination: correlation with HIV serology and with immunological parameters. J. Med. Virol. 40:91-95, 1993.

16. Rakocz M., Mazar A., Varon D., Spierer S. & Martinowitz U.: Dental extractions in patients with bleeding disorders, the use of fibrin glue. Oral Surg. Oral Med. Oral Pathol. 75: 280-282, 1993.

17. Greenspoon N., Hershkoviz R., Alon R., Varon D., Shenkman B., Marx G., Federman S., Kapustina G. & Lider O.: Structural analysis of integrin recognition and inhibition of integrin-mediated cell functions by novel non-peptidic surrogates of the Arg-Gly-Asp sequence. J. Biochem. 32:1001-1008, 1993.

18. Dardik R., Ruggery Z.M., Savion N., Gitel S, Martinowitz U., Chu V. & Varon D.: Platelet aggregation on extracellular matrix: effect of a recombinant GPIb-binding fragment of von-Willebrand factor. Thromb. Haemost. 3:522-526, 1993.

19. Varon D., Lider O., Dardik R., Shenkman B., Alon R., Hershkoviz R., Kapustina G., Savion N., Martinowitz U. & Greenspoon N.: Inhibition of Integrin-Mediated Platelet Aggregation, Fibrinogen-binding, and Interactions with Extracellular Matrix by Nonpeptidic Mimetic of Arg-Gly-Asp. Thromb. Haemostas. 70:1030-1036, 1993.

20. Neuman Y., Toren A., Mandel M., Martinowitz U., Varon D., Ramot B., Ben-Bassat I., and Rechavi G. Favorable response of pediatric AIDS-related Burkitts lymphoma treated by aggressive chemotherapy. Med. Pediat. Oncol. 21:661-664,1993.

21. Berg L-P., Varon D., Martinowitz U., Wieland K., Kakkar VV. and CooperD: Combined factor VIII-factor XI deficiency: a case of intra-familial clinical clinic variability in hemophilia A among Ashkenazi Jews? Blood Coagulation and Fibrinolysis 5: pp.59-62, 1994.

22. Schulman S., Varon D., Keller N., Gitel S. & Martinowitz U.: Monoclonally purified F VIII for continuous infusion: stability, microbiological safety and clinical experience. Thromb. Haemostas. 72(3), Sept. 1994.

23. Varon D., Schulman S., Dardik R., Barzilai A., Bashari D., and Martinowitz U: High versus ultra-purity factor VIII concentrate therapy: Prospective evaluation of immunological and clinical parameters in HIV seronegative and seropositive hemophilics. Thromb. Haemostas. 72(3), Sept. 1994.

24. Barzilai A., Schulman S., Karetnyi YV., Favorov MO., Levin E., Mendelson E., Weiss P., Fields HA., Varon D. and Martinowitz U.: Hepatitis E Virus infection in Hemophiliacs. J. of Med. Virology 46:153-156, 1995. (2.867, 7/26, 11, 11)

25. Schulman S., Gitel S.N., Zivelin A., Mandalaki T., Katsarou O., Varon D. & Martinowitz U.: The feasibility of using factor IX concentrates for continuous infusion. Haemophilia 1: 103-110, 1995. (0.748, 43/59, 17, 14).

26. D. Varon: Prospective clinical trial of high purity factor VIII preparations in haemophiliacs. Blood Coag and Fibrin. 6(2) S82-83, 1995. (1.390, 29/59)

27. Schulman S., Bech Jensen M., Varon D., Keller N., Gitel S., Horoszowski H., Heim M.Heim M. and Martinowitz U.: Feasibility of using recombinant factor VIIa in continuouscontinuous infusion. Thromb and Hemostas. 75(3) 432-436, 1996. (4.983, 6/59, 6/44, 43, 41).

28. Varon D., Schulman S., Bashari D. and Martinowitz U.: Home therapy with continuous infusion of factor VIII after minor surgery orserious haemorrhage. Haemophilia 2, 207-210, 1996. (0.748, 43/59, 6,4).

29. Yosefy C., Viskoper JR., Varon D., Han Z., Pilpel D., Lugassy G., Scneider R., Savion N., Adan Y. and Raz A.: Repeated fasting and re feeding with 20:5, n-3 Eicosapentaenoic acid (EPA) supplement: A novel approach for rapid fatty acid exchange and its effect on blood pressure, plasma lipids and hemostasis. J of Human Hypertension, 10 (3), S135-139, 1996. (1.151, 26/44, 6,4).

30. Horoszowski H., Heim M., Schulman S., Varon D., Martinowitz U. : Multiple joint procedures in a single operative session on hemophilic patients. Clin Ortho.and related research, 328, 60-64, 1996. (1,251, 7/42, 3,2)

31. Varon D., Dardik R., Shenkman B., Kotev-Emeth S., farzame N., Tamarin I. and Savion N.: Primary hemostasis analyzer (PHA): A new method for quantitative analysis of primary hemostasis measuring whole blood platelet interaction with extracellular matrix under defined flow conditions. Thromb.Research, 85(4), 283-294, 1997 (1,207, 33/59, 23/44, 23/8)

32. Dardik R., Kaufman Y., Savion N., Rosenberg N., Shenkman B. and Varon D.: Platelets mediate tumor cell adhesion to the subendothelium under flow conditions: Involvement of platelet GPIIb-IIIa and tumor cell av integrins. inter. J. Cancer 70, 201-207, 1997 (3.545, 15/105, 12,10)

33. ENOXACAN study group: The efficacy and safety of enoxaparin vs. unfractionated heparin in prevention of deep vein thrombosis in elective cancer surgery. A double-blind randomized multicentre trial in 1116 patients with venographic assessment. British J of Surgery. 84,1099-1103,1997 (2.732, 11/131, 5,5).

34. George J., Blank M., Gilburd B., Hojnik M., Shenkman B., Tamarin I., Varon D., Matsuura E., Koike T., Shoenfeld Y: Immunologic characterization and functional properties of murine antibodies raised against deleted mutants of human b₂ glycoprotein. Int Immunol. 9 (6), 913-921,1997 (2.897, 25/115, 8,8)

35. G. Kenet, A. lubetski, B. Shenkman, I. Tamarin, R. Dardik, G. Rechavi, A. Barzilai, U. Martinowitz, N. Savion and D. Varon Cone and Platelet Analyser (CPA): a new test for the prediction of bleeding among thrombocytopenic patients. British J. Haematol. 101, 255-259, 1998 (3.204, 12/59, 3,3)

36. Varon D., Jackson DE., Shenkman B., Dardik R., Tamarin I., Savion N., and Newman PJ.: Platelet/Endothelial Cell Adhesion Molecule-1 serves as a costimulatory receptor that modulates integrin-dependent adhesion and aggregation of human platelets. Blood91:500-507, 1998. (8.782, 2/59, 28,28).

37. Dardik R., Savion N., Kaufman Y. and Varon D.: Thrombin promotes platelet-mediated melanoma cell adhesion to endothelial cells under flow conditions: role of platelet glycoproteins P-selectin and GPIIb-IIIa. British J Canc Res. 77:2069-2075. 1998. (3.282, 17/105, 8,5)

38. Knobler H., Savion N., Shenkman B. Kotev-Emeth S. and Varon D: Shear-Induced platelet adhesion and aggregation on subendothelium are increased in diabetic patients. Thromb Res. 90:181-190, 1998. (1.207, 33/59, 8,7)

39. D. Varon and U. Martinowitz: Continuous infusion in haemophilia. Haemophilia 1998;4: 431-435 (0.748, 43/59, 3,3)

40. U. Martinowitz, D. Varon and M. Heim: The role of fibrin tissue adhesives in surgery of hemophilia patients. Haemophilia 1998; 4:443-448 (0.748, 43/59, 4,4)

41. O. Gurevitz, A. Goldfarb., H. Hod., M. Feldman., B. Shenkman, D. Varon, M. Eldar, A. Inbal: Recombinant von Willebrand factor fragment AR545C inhibits platelet aggregation and enhances thrombolysis with rtPA in a rabbit thrombosis model. ATVB 1998; 18(2):200-7 (5.406, 5/59, 5,3)

42. B. Dekel, H. Marcus, B. Shenkman., A. Shimoni., Y. Shechter., A. Canaan, A. Berrebi., D. Varon., Y. Reisner: Human/BALB radiation chimera engrafted with splenocytes from patients with idiopathic thrombocytopenic purpura produce human platelet antibodies. Immunology 1998; 94(3):410-6 (2.575, 32/115).

43. D. Varon., I. Lashevski., B. Brenner., Beyar R., N. Lanir., I. Tamarin., N. Savion: Cone and plate(let) analyzer: Monitoring glycoprotein IIb/IIIa antagonists and von Willebrand disease replacement therapy by testing platelet deposition under flow conditions. Am H J 1998;135:s 187- s 193. (2.021, 16/67, 10,4)

44. R. Kantor, A. Barzilai, D. Varon, U Martinowitz and JM. Gershoni: Prevalence of a CCR5 gene 32-bp deletion in an Israeli cohort of HIV-1-Infected and uninfected hemophilia patients. J Human Virol 1998;1:299-301.

45. B. Shenkman., N. Linder., N. Savion., I. Tamarin., R. Dardik., G. Kenet., B. German and D. Varon: Increased Neonatal Platelet Deposition on Subendothelium Under flow conditions: The role of plasma von Willebrand factor. Pediatric res. 1999;45(2) (2.671, 4/72, 2,1)

46. A. Lubetzky., S. Schulman., D. Varon., U. Martinowitz, G. Kenet., G. Sanford., A. Inbal: Safety and efficacy of continuous infusion of a combined factorVIII-von Willebrand factor (vWF) concentrate (Haemate-P™) in patients with von Willebrand Disease. Thromb Haemost 1999; 81 (2), 229-233. (4.983, 6/59, 2,2)

47. Ophira S, Steinberg D, Zivelin A, Gitel S, Dardik R, Rosenberg N, Berliner S, Inbal A, Lubetsky A, Varon D and Seligshon U: Single and combined prothrombotic factors in patients with idiopathic venous thromboembolism – prevalence and risk assessment. Arterioscler Thromb Vasc Biol 1999; 19:511-518. (5.406, 5/59, 5/44, 27/27)

48. Shenkman B, Rubinstein E, Dardik R, Tamarin I, Savion N and Varon D: Activated platelets mediate staphylococcus aureus deposition on subendothelial extracellular matrix: the role of glycoprotein Ib. Platelets 1999; 10:36-44. (0.882, 40/59, 1,0)

49. Barzilai A, Varon D, Martinowitz U, Heim M and Schulman S: Characteristics of septic arthritis in human immunodeficiency virus-infected haemophiliacs versus other risk groups. Rheumatology 1999; 38:139-142.

50. Yosefy C, Viskoper R, Laszt A, Priluk R, Guita E, Varon D, Illan Z, Berry EM, Savion N, Adan Y, Lugassy G, Schneider R and Raz A : The effect of fish oil on hypertension plasma lipids and hemostasis in hypertensive, obese, dyslipidemic patients with and without diabetes mellitus. Prostaglandins, Leukotrienes and Essential Fatty Acids1999; 61, 83-87. (1.091, 106/141, 55/85, 202/295, 2,2)

51. Inbal A, Gurevitz O, Tamarin I, Eskaraev R, Chetrit A, Novicov I, Feldman M, Varon D , Eldar M and Loscalzo J. (1999). Unique antiplatelet effects of a novel S-Nitrosoderivative of a recombinant fragment of von Willebrand factor, AR545C: In vitro and Ex Vivo Inhibition of platelet function. Blood, 1999; 94: 1693-1700.( 8.782, 2/59, 3,3)

52. Brill AG, Brill GE, Kirichuk VF, Shenkman B, Tamarin I, Dardik R, Varon D, Savion N: Influence of Ne-Nen laser radiation on platelet activation and aggregation. Buil Exp Biol Med 1999; 7:48-50.

53. Heim M, Wershavski M, Martinowitz U, Varon D, Checick A and Azaria M: The role of orthoses in the management of elbow joints in persons with haemophilia. Haemophilia 1999; 5:43-45. (0.748, 43/59)

54. Brill AG, Shenkman B, Brill GE, Tamarin I, Dardik R, Kirichuk VF, Savion N and Varon D: Blood irradiation by He-Ne laser induces a decrease in platelet responses to physiological agonists and an increase in platelet cyclic GMP. Platelets 2000;11: 87-93. (0.882, 40/59)

55. Shenkman B, Rubinstein E, Tamarin I, Dardik R, Savion N and Varon D: Staphylococcus aureus adherence to thrombin treated endothelial cells is mediated by fibrinogen but not by platelets. J Lab Clin Med 2000;135: 43-51. (1.898, 6/26, 20/110, 24/76, 1,1)

56. Dardik R, Varon D, Eskaraev R, Tamarin I and Inbal A: Recombinant fragment of von Willebrand factor AR545C inhibits platelets binding to thrombin and platelet adhesion of thrombin- treated endothelial cells. British J. of Haematol 2000; 109: 512-518. (3.204, 12/59)

57. Kenet G, Lubetsky A, Gitel S, Luboshitz J, Varon D and Martinowitz U:Treatment of bleeding episodes in patients with hemophilia and an inhibitor: comparison of two treatment protocols with recombinant activated factor VII. Blood Coag and Fib 2000;11:35-38. (1.390, 29/59, 1,1)

58. Schneiderman J, Benyamina M, Gerniak A, Rimon U, Varon D, Seligshon U, Shotan A and Adar R: Abciximab in carotid stenting for postsurgical carotid restenosis: intermediate results. J Endovasc Ther 2000; 7: 263-72.

59. Dardik R, Varon D, Tamarin I, Zivelin A, Salomon O, Shenkman B and Savion N. Homocysteine and oxidized low density lipoprotein enhance platelet adhesion to endothelial cells under flow conditions: distinct mechanisms of thrombogenic modulation. Thromb Haemost 2000;83: 338-344. (4.893, 6/59)

60. Ariel A, Lider O, Brill A, Cahalon L, Savion N, Varon D and Hershkoviz R: Induction of interactions between CD44 and hyaluronic acid by a short exposure of human T cells to diverse pro-inflammatory mediators. Immunology 2000; 100:345-351 (2.575, 32/115, 1,1).

61. Shenkman B, Savion N, Dardik R, Tamarin I and Varon D: Testing of platelet deposition on polystyrene surface under flow conditions by the cone and plate(let) analyzer: role of platelet activation, fibrinogen and von Willebrand factor. Thromb. Res. 2000;99: 353-361. (1.207, 33/59)

62. Savion N, Shenkman B, Tamarin I, Dardik R, Frojmovic M and Varon D: Transient adhesion refractoriness of circulating platelets under shear stress: the role of partial activation and microaggregate formation by suboptimal ADP concentration. Brit. J. Hematol 2001, 112, 1055-1061, (3.204, 12/59)

63. Osende JI, Fuster V, Lev E, Shimbo D, Rauch U, Marmur J, Richard M, Varon D, Badimon JJ: Testing platelet activation with a shear-dependent platelet function test versus aggregation - based tests. Relevance for monitoring long term Glycoprotein IIb/IIIa inhibition. Circulation 2001;807:29-35 (9.903, 1/59)

64. Shenkman B, Schneiderman J, Tamarin I, Kotev-Emeth S, Savion N and Varon D: Testing the effect of GPIIb-IIIa antagonist in patients undergoing carotid stenting: correlation between standard aggregometry, flow cytometry and the cone and plate (let) analyzer (CPA) methods. Thromb. Res. 2001. 102(4): 311-7. (1.207, 33/59)

65. Shenkman B, Rubinstein E, Cheung AL, Brill GE, Dardik R, Tamarin I, Savion N and Varon D: Adherence properties of Staphylococcus Aureus under static flow conditions: the role of agr and sar loci as well as of platelets and plasma ligands. Infections and Immunity. 2001 69(7): 4473-8. (4.184, 15/115, 4/35)

66. Merli, G., Spiro, TE., et al, for the Enoxaparin clinical trial Group: Subcutaneous enoxaparin once or twice daily compared with intravenous unfractionated heparin for treatment of venous thromboembolic disease. Ann. Intern. Med. 2001; 134: 191-202.

6 Varon D. and Brill A. : Platelet cross-talks with tumor cells. Haemostasis 2001; 31 Suppl 1:64-6.

68. Sherer Y., Bitzur R., Cohen H., Shaish A., Varon D, Shoenfeld Y., Harats D.: Mechanisms of action of the anti-atherogenic effect of magnesium: lesson from a mouse Model. Magnes. Res. 2001; 14: 173-9.

69. Linder N., Shenkman B., Levin E., Sirota L., Vishne TH., Tamarin I., Dardik R., Lubin D., Savion N. and Varon D.: Whole blood platelets deposition on extracellular matrix under flow conditions in perinatal infants. Arch. Dis. Child. Fetal neonatal ed. 2002; 86: 127-30.

70. Finkelstein Y., Shenkman B., Sirota L., Vishne TH., Dardik R., Varon D., Linder N.: Whole blood platelets deposition on extracellular matrix under flow conditions in preterm neonatal sepsis. Eur J Pediatr. 2002; 161: 270-4.

71. Dardik R., Shenkman B., Tamarin I., Eshkarev R., Harsfalvi J., Varon D., Inbal A. Factor XIII mediatets adhesion of platelets to endothelial cells through alpha (V) beta (3) and Glycoprotein IIb/IIIa integrins. Thromb Res 2002; 105: 317-23.

72. Dotan ZA., Mor Y., Leibovitch I., Varon D., Golomb J., Duvdevani M., Ramon J. The Efficacy and safety of perioperative low molecular weight heparin substitution in patients on chronic oral anticoagulant therapy undergoing transurehral prostatectomy for bladder outlet obstruction. J Urol 2002; 168: 110-3 discussion 614.

73. Shenkman B., Varon D., Tamarin I., Dardik R., Peisachov M., Savion N., Rubinstein E. Role of agr (RNA III) in Staphylococcus aureus adherence to fibrinogen, fibronectin, Platelets and endothelial cells under static and flow conditions. J Med Microbiol. 2002; 51: 747-54.

74. Fallgren C., Ljungh A., Shenkman B., Varon D., Savion N. Venous shear stress enhances platelet mediated Staphylococcal adhesion to artificial and damaged biological surfaces. Biomaterials. 2002; 23: 4581-9.

75. Wang X., Dorsam RT., Lauver A., Wang H., Barbera FA., Gibbs S., Varon D., Savion N., Friedman SM., Feuerstein GZ. Comparative analysis of various platelets GPIIb/IIIa Antagonists: Shear induced platelet activation and adhesion. J Pharmacol Exp Ther. 2002: 303; 1114-20.

76. Varon D., Knobler ., Coslovsky R., Dardik R., Shenkman B., Tamarin I, Savion N.: Increased platelet adhesion and aggregation on sub-endothelium in NIDDM: Correlation with diabetic dyslipidemia. 14^th International Congress on Thrombosis. Montpellier, France, 1996.

77. Kenet G., Lubetsky A., Shenkman B., Tamarin I., Dardik R., Savion N., Martinowitz U. and Varon D.: Primary hemostasis analyzer (PHA) test for the prediction of bleeding among thrombocytopenic patients. ASH Meeting, Orlando, Florida 1996

78. Varon D., Dardik R., Shenkman B., Tamarin I., Quintana M., Jensana M., Martinowitz U, Savion N.: Platelet interaction with ECM under shear flow conditions as a new method for the diagnosis and monitoring of replacement therapy in von Willebrand disease. XVIth Congress of the International Society on Thrombosis and Haemostasis. Florence, Italy, 1997.

79. Martinowitz U., Schulman S., Gitel S., Keller N., Lubetzky A. and Varon D.: Preliminary evaluation of factor VIII/vWF concentrate (FANHDI®) for continuous infusion: stability and bacteriology safety. XVIth Congress of the International Society on Thrombosis and Haemostasis. Florence, Italy, 1997.

80. Dardik R., Savion N., Kaufmann Y., Shenkman B., Tamarin I. And Varon D.: Activated platelets mediate tumor cells adhesion to vascular endothelium under flow conditions. XVIth Congress of the International Society on Thrombosis and Haemostasis. Florence, Italy, 1997.

81. Savion N., Tamarin I., Shenkman B., Dardik R. & Varon D.: Transient adhesion refractoriness of platelets following interaction with extracellular matrix under flow conditions. XVIth Congress of the International Society on Thrombosis and Haemostasis. Florence, Italy, 1997.

82. Varon D., Shenkman B., Dardik R., Tamarin I., Savion N., Jackson D. and Newman PJ.: Monoclonal antibodies specific for PECAM-1 1g-domain 6 promote platelet activation in vitro. XVI Congress of the International Society on thrombosis, Florence, Italy, 1997.